Top federal health officials say that psychedelics have “promising” therapeutic potential—but research into them has been stymied by ongoing federal prohibition. They also argue that as the Food and Drug Administration (FDA) considers approving substances like psilocybin, it’s important to look at issues such as accessibility, affordability, health care reimbursements and ethics. In an opinion … Continue reading Top Federal Health Officials Say Psychedelics’ Schedule I Status Creates ‘Hurdles’ To Studying Them